Does guided selection of P2Y12-inhibiting therapy improve the balance between safety and efficacy compared to potent P2Y12 inhibitor therapy in patients with acute coronary syndrome?
Guided selection of P2Y12-inhibiting therapy offers the most favorable balance of safety and efficacy in patients with acute coronary syndrome, supporting its broader adoption.
A guided selection of P2Y12-inhibiting therapy represents the strategy associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided P2Y12 inhibiting therapy in patients with acute coronary syndrome.
Galli et al. (2021) studied this question.